A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 3 Concentrations of Topically Applied BBI-4000 (Sofpironium Bromide) Gel in Subjects With Axillary Hyperhidrosis
Latest Information Update: 18 May 2023
At a glance
- Drugs Sofpironium bromide (Primary)
- Indications Hyperhidrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Brickell Biotech; Fresh Tracks Therapeutics
- 15 Apr 2021 According to a Brickell Biotech Inc media release, results from this trial were published in the peer-reviewed Journal of Drugs in Dermatology.
- 15 Apr 2021 Results published in the Brickell Biotech Inc Media Release.
- 20 Feb 2020 According to a Brickell Biotech media release, results of this trial is now available online (Journal Pre-proof) at (https://doi.org/10.1016/j.jaad.2020.02.016) and will be published in a future print edition of Journal of the American Academy of Dermatology (JAAD).